Sentences with phrase «treatment study of»

We further explain our complicated grief model and provide results of a study of 128 participants in a treatment study of CG who completed a 15 - item Grief - related Avoidance Questionnaire (GRAQ).

For example, the Multimodal Treatment Study of Children with ADHD (MTA) is the most comprehensive intervention study to date in this population.

A recent study8 examining peer status in clinically - diagnosed 7 — 9 year old children with ADHD from the Multimodal Treatment Study of Children With ADHD (MTA) 9,10 found that 52 % fell in the rejected category (when the classification system of Coie et al11 is used) and less than 1 % were of popular status.8 When children who did not fit into any category were excluded in calculating these percentages, the situation was even more bleak, with 80 % of children with ADHD falling in the rejected group.8 These figures are consistent with previous work indicating that 82 % of children with ADHD have peer rejection scores one standard deviation or more above the mean and 60 % are two standard deviations or more above the mean.12

The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD / HD: a supplement to the NIMH multimodal treatment study of AD / HD

[jounal] Hoza, B. / 2005 / Peer - assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder / Journal of Clinical Child and Adolescent Psychology 34: 74 ~ 86

Treatment of Children With Attention - Deficit / Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA).

Learn more about the Multimodal Treatment Study of Children with ADHD and results from this large research study.

In the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA) study of

In the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA) study of large numbers of children with ADHD and various coexisting conditions, behavioral treatments were equally as effective as medication treatment for children with ADHD and parent - reported anxiety symptoms.

Although this possibility can not be ruled out, it does not seem probable because the teacher - rated hyperactivity factor score of this cohort was 2.11 (0.46)(on a scale of 0 to 3), which is somewhat higher than the Multimodal Treatment Study of Children with ADHD sample, which had a score of 1.82 (0.49)(no other longitudinal study reports teacher ratings).

The National Institute of Mental Health Collaborative Multisite Multimodal Treatment Study of Children with Attention Deficit / Hyperactivity Disorder

Estimates of prevalence of conduct disorder in children with ADHD vary.38 In the Multimodal Treatment Study of Children with ADHD, which included children of both sexes and all racial groups, the rate of conduct disorder was 14.3 %.39 Therefore, study findings appear relevant to most children with ADHD.

Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers

National institute of mental health multimodal treatment study of ADHD follow - up: 24 - month outcomes of treatment strategies for attention - deficit / hyperactivity disorder.

Known as the Multimodal Treatment Study of ADHD (MTA Study), it involved more than 570 ADHD children at 6 sites in the United States and Canada randomly assigned to 4 treatment groups.

He has authored over 300 publications, including several books, and is the recipient of numerous National Institutes of Health grants for developing integrated group therapy, as well as leading a multisite treatment study of prescription opioid dependence.

In a 16 - year follow - up of the Multimodal Treatment Study of Children with ADHD (the «MTA»), they found that a combination of parent and self - reports plus a symptom threshold that is adjusted for adulthood (rather than based on traditional childhood definitions of ADHD) may be optimal.

Conducted over two years, the Multimodal Treatment Study of Children with ADHD included 579 ADHD children at six different university medical centers.

In fact, most of the treatment studies of psychopaths have been marred by serious methodological problems.

The Sleep Impairment Index has adequate psychometric properties and has been shown sensitive to changes in previous treatment studies of insomnia.24, 25

Not exact matches

An important trigger this year will be the outcome of a study where Darzalex is being tested as first - line treatment in combination with Celgene Corp's Revlimid.

Lilly faced a devastating clinical setback last year with a late - stage failure for its experimental Alzheimer's treatment, the studies for which cost the company hundreds of millions of dollars.

Furthermore, an early - stage study pumping up the dose of its hemophilia A treatment — which aims to be a one - time therapy for the rare blood clotting - related disease — appeared to hit its targets without serious side effects.

It studies DNA in the blood, detecting biological signs of cancer and then making predictions about where the cancer is and what kind of treatments would work best.

As a result, «we are building on these findings to refine existing treatments to boost feelings of being safe and supported in order to improve coping with traumatic memories,» said Dr. Anke Karl, one of the authors, wrote of the study.

At Battelle, Koper is studying the use of nanomaterials in membranes for water desalination and treatment; supercapacitors (energy - storage devices that provide higher power densities than batteries); and bio-based (rather than petroleum - based) additives used for hydraulic fracturing, or fracking, to retrieve natural gas.

Which is a shame, because according to at least one recent study, there are actually three distinct types of burnout that demand three different types of treatment.

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

VICE News made numerous email and telephone queries over the past month to spokespeople for the Army, the Navy, and the Department of Defense seeking comment on the Army Institute of Public Health study and the treatment of troops before and after their deployment to Guantanamo.

Private hospitals are typically the best equipped, with state - of - the art technology and doctors that have studied in the world's best medical universities — many of them speak English and are well acquainted with the newest diagnostic and treatment procedures... some of which may not yet be available in the U.S., for example.

That's striking because the treatment is part of a class called CETP medicines which haven't proven particularly successful in previous studies.

The growing number of people who have the disease is troubling, because there are only four approved drugs that treat symptoms of the disease, and several hopeful treatments have failed key studies in 2017.

Besides randomized controlled clinical trials, there are a number of ways researchers can study how a particular cancer treatment is playing out in the real world: there are retrospective studies, observational studies, and even prospective research done using patient registries.

In a late - stage study, Aimmune, a biotech immunotherapy allergy treatment taken via pill, found that of the roughly 500 kids with peanut allergies between the ages of 4 - 17 who were part of the trial, 67 % of those who received the treatment were able to tolerate 600 milligrams of peanut protein (about two to four peanuts) after about a year of treatment, while only 4 % of those who got the placebo could tolerate that dose of peanut protein.

While the research was aimed at eventually developing treatments for those suffering from PTSD, the study authors said these initial findings were also useful for those of us who just have to deal with normal negativity like marital spats and nasty work disagreements.

Once the final results of those studies are analyzed this spring — and the early evidence has been encouraging — the challenge will be to get FDA approval for human trials and then bring the treatment to market.

The study is particularly encouraging because autism diagnoses are currently done on children between the ages of two and four, and earlier diagnoses allows for more effective treatment measures.

Pagan said that a larger, more comprehensive study must be done before determining the drug's true impact, but if the drug's effectiveness is confirmed in such tests, nilotinib could become the first treatment to impede the killing of brain cells that's consistent with Parkinson's, according to NPR.

«More than twice the number of patients [were] still living at the end of the study after receiving IMAB362 plus chemotherapy compared to chemotherapy alone,» according to Ganymed CEO Özlem Türeci, with patients showing the highest level of that protein biomarker responding best to the treatment.

The Food and Drug Administration (FDA) has given Alnylam Pharmaceuticals the green light to relaunch clinical trials of its treatment for the bleeding disorder hemophilia after pausing the studies after a patient death.

Through week 48, Biktarvy was found to be statistically non-inferior to ABC / DTG / 3TC with a numerically lower incidence of mild or moderate study drug - related adverse events and no treatment - emergent resistance;

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The new study tested Keytruda as a standalone treatment, rather than as part of a combination of meds.

«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.

To my mind, the adopting release's treatment of the economic studies is not evenhanded.

Living Goods told us at that time that the results from the RCT were not going to be reliable due to spillover of the intervention into control locations and incorrect matching of the treatment area and the treatment survey area — issues that reduce the statistical power of the study.1

This test confirmed a significant positive effect of treatment on investment in high variance stocks, both for the cortisol administration study (z = 2.37, P = 0.018) and the testosterone administration study (z = 2.04, P = 0.041, see Fig.

According to a recent study by David Macdonald of the Canadian Centre for Policy Alternatives, almost all of the tax benefit of special tax treatment of dividends (91 %) goes to the top one tenth of all tax filers.

The RadioShack proceedings offer an interesting case study in the treatment of unitranche lenders under two agreements among lenders that existed in that case.